Cambium Bio Ltd (AU:CMB) — Market Cap & Net Worth
Market Cap & Net Worth: Cambium Bio Ltd (CMB)
Cambium Bio Ltd (AU:CMB) has a market capitalization of $6.66 Million (AU$9.42 Million) as of May 6, 2026. Listed on the AU stock exchange, this Australia-based company holds position #27781 globally and #1472 in its home market, demonstrating a -6.82% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cambium Bio Ltd's stock price AU$0.41 by its total outstanding shares 22968281 (22.97 Million). Analyse CMB cash generation efficiency to see how efficiently the company converts income to cash.
Cambium Bio Ltd Market Cap History: 2015 to 2026
Cambium Bio Ltd's market capitalization history from 2015 to 2026. Data shows change from $149.32 Million to $6.66 Million (-27.23% CAGR).
Cambium Bio Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cambium Bio Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.40x
Cambium Bio Ltd's market cap is 11.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $262.10 Million | $1.74 Million | -$3.57 Million | 151.03x | N/A |
| 2017 | $198.56 Million | $9.99 Million | $3.27 Million | 19.87x | 60.71x |
| 2018 | $285.93 Million | $575.41K | -$5.18 Million | 496.92x | N/A |
| 2019 | $141.39 Million | $25.08K | -$6.02 Million | 5638.16x | N/A |
| 2020 | $203.14 Million | $1.66 Million | -$894.05K | 122.13x | N/A |
| 2021 | $130.01 Million | $7.07 Million | $2.76 Million | 18.40x | 47.12x |
| 2024 | $6.50 Million | $719.00 | -$2.26 Million | 9041.18x | N/A |
| 2025 | $7.64 Million | $670.06K | -$3.84 Million | 11.40x | N/A |
Competitor Companies of CMB by Market Capitalization
Companies near Cambium Bio Ltd in the global market cap rankings as of May 6, 2026.
Key companies related to Cambium Bio Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.67 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $72.97 Billion USD.
- UCB SA (BR:UCB): Ranked #515 globally with a market cap of $51.41 Billion USD ( €43.97 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #570 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.67 Billion | $424.36 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.97 Billion | $702.27 |
| #515 | UCB SA | BR:UCB | $51.41 Billion | €231.00 |
| #570 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Cambium Bio Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Cambium Bio Ltd's market cap moved from $149.32 Million to $ 6.66 Million, with a yearly change of -27.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$6.66 Million | -12.77% |
| 2025 | AU$7.64 Million | +17.50% |
| 2024 | AU$6.50 Million | +33.33% |
| 2023 | AU$4.88 Million | -93.75% |
| 2022 | AU$78.01 Million | -40.00% |
| 2021 | AU$130.01 Million | -36.00% |
| 2020 | AU$203.14 Million | +43.68% |
| 2019 | AU$141.39 Million | -50.55% |
| 2018 | AU$285.93 Million | +44.00% |
| 2017 | AU$198.56 Million | -24.24% |
| 2016 | AU$262.10 Million | +75.53% |
| 2015 | AU$149.32 Million | -- |
End of Day Market Cap According to Different Sources
On May 6th, 2026 the market cap of Cambium Bio Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.66 Million USD |
| MoneyControl | $6.66 Million USD |
| MarketWatch | $6.66 Million USD |
| marketcap.company | $6.66 Million USD |
| Reuters | $6.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cambium Bio Ltd
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing i… Read more